Trial · NCT01703988
Results by group65
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 65
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 3 mg | Any AE | 8 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 6 mg | Any AE | 6 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 9 mg | Any AE | 9 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 12 mg | Any AE | 9 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 3 mg | Any drug-related AE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 6 mg | Any drug-related AE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 9 mg | Any drug-related AE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 12 mg | Any drug-related AE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 3 mg | Any SAE | 2 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 6 mg | Any SAE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 9 mg | Any SAE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 12 mg | Any SAE | 1 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 3 mg | Discontinued due to an AE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 6 mg | Discontinued due to an AE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 9 mg | Discontinued due to an AE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 12 mg | Discontinued due to an AE | 0 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 3 mg | Highest severity of AE=mild | 2 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 6 mg | Highest severity of AE=mild | 2 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 9 mg | Highest severity of AE=mild | 6 | Participants | |
| Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuations Due to AEs, and Highest Severity of AEs | Nusinersen 12 mg | Highest severity of AE=mild | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01703988/results